10 top therapy areas for payers right now

Vaccines and anti-infectives are among the highest therapy priorities for U.S. health plans, according to a report from consulting and professional services firm ZS. 

The report surveyed payers around the world to better understand their perspective on the COVID-19 pandemic and what it could mean for the industry. ZS conducted 45-minute surveys with 25 global health plans from March 30 to April 7.

Here are the 10 therapy areas U.S. payers said they are prioritizing right now, ranked from highest to lowest:

1. Vaccines
2. Anti-infectives
3. Oncology
4. Cell and gene therapy
5. Biosimilars
6. Acute care medicines
7. Autoimmune diseases 
8. Orphan diseases 
9. Generics 
10. Medical devices

Access the full report here

More articles on payers:
UnitedHealth to give members $1.5B in discounts
Humana waives costs for primary care, behavioral health visits for 4.5 million members
Health Care Service Corp. taps new CEO

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers